245 related articles for article (PubMed ID: 6882032)
1. Polymyalgia rheumatica and corticosteroids: how much for how long?
Behn AR; Perera T; Myles AB
Ann Rheum Dis; 1983 Aug; 42(4):374-8. PubMed ID: 6882032
[TBL] [Abstract][Full Text] [Related]
2. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months.
Kyle V; Hazleman BL
Ann Rheum Dis; 1989 Aug; 48(8):658-61. PubMed ID: 2782975
[TBL] [Abstract][Full Text] [Related]
3. Polymyalgia rheumatica and giant cell arteritis: a seven-year survey.
Myles AB
Rheumatol Rehabil; 1975 Nov; 14(4):231-5. PubMed ID: 1198014
[TBL] [Abstract][Full Text] [Related]
4. The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment.
Kyle V; Hazleman BL
Ann Rheum Dis; 1993 Dec; 52(12):847-50. PubMed ID: 8311533
[TBL] [Abstract][Full Text] [Related]
5. Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects.
Kyle V; Hazleman BL
Ann Rheum Dis; 1989 Aug; 48(8):662-6. PubMed ID: 2782976
[TBL] [Abstract][Full Text] [Related]
6. Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis.
Lundberg I; Hedfors E
J Rheumatol; 1990 Oct; 17(10):1340-5. PubMed ID: 2254893
[TBL] [Abstract][Full Text] [Related]
7. Treatment of polymyalgia rheumatica/giant cell arteritis.
Kyle V
Baillieres Clin Rheumatol; 1991 Dec; 5(3):485-91. PubMed ID: 1807823
[TBL] [Abstract][Full Text] [Related]
8. Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis. A prospective two-year study in 273 patients.
Myklebust G; Gran JT
Scand J Rheumatol; 2001; 30(5):260-7. PubMed ID: 11727839
[TBL] [Abstract][Full Text] [Related]
9. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients).
Delecoeuillerie G; Joly P; Cohen de Lara A; Paolaggi JB
Ann Rheum Dis; 1988 Sep; 47(9):733-9. PubMed ID: 3178314
[TBL] [Abstract][Full Text] [Related]
10. Adrenal insufficiency in prednisolone-treated patients with polymyalgia rheumatica or giant cell arteritis-prevalence and clinical approach.
Borresen SW; Thorgrimsen TB; Jensen B; Hilsted L; Bartels EM; Feldt-Rasmussen U; Locht H
Rheumatology (Oxford); 2020 Oct; 59(10):2764-2773. PubMed ID: 32031663
[TBL] [Abstract][Full Text] [Related]
11. Giant cell arteritis precipitated by a diagnostic trial of prednisolone in suspected polymyalgia rheumatica.
Reilly PA; Maddison PJ
Clin Rheumatol; 1987 Jun; 6(2):270-2. PubMed ID: 3621844
[TBL] [Abstract][Full Text] [Related]
12. [A case of giant cell arteritis after prednisolone dose reduction during treatment of polymyalgia rheumatica].
Yamashita M; Aoki A; Kobayashi H; Wakiya M; Nakatsugawa M
Nihon Ronen Igakkai Zasshi; 2023; 60(4):440-447. PubMed ID: 38171762
[TBL] [Abstract][Full Text] [Related]
13. Prognosis of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. A follow-up study on ninety patients treated with corticosteroids.
Bengtsson BA; Malmvall BE
Acta Med Scand; 1981; 209(5):337-45. PubMed ID: 7246269
[TBL] [Abstract][Full Text] [Related]
14. Homocysteine levels in polymyalgia rheumatica and giant cell arteritis: influence of corticosteroid therapy.
Martinez-Taboada VM; Bartolome MJ; Fernandez-Gonzalez MD; Blanco R; Rodriguez-Valverde V; Lopez-Hoyos M
Rheumatology (Oxford); 2003 Sep; 42(9):1055-61. PubMed ID: 12730520
[TBL] [Abstract][Full Text] [Related]
15. Polymyalgia rheumatica and giant cell arteritis--An ophthalmic emergency.
Durkin SR; Athanasiov PA; Crompton JL
Aust Fam Physician; 2006 Nov; 35(11):889-91. PubMed ID: 17099810
[TBL] [Abstract][Full Text] [Related]
16. Prognosis and management of polymyalgia rheumatica.
Jones JG; Hazleman BL
Ann Rheum Dis; 1981 Feb; 40(1):1-5. PubMed ID: 7469518
[TBL] [Abstract][Full Text] [Related]
17. [Treatment and diagnosis of polymyalgia rheumatica and temporal arteritis].
Gran JT
Tidsskr Nor Laegeforen; 2003 Dec; 123(23):3387. PubMed ID: 14713975
[TBL] [Abstract][Full Text] [Related]
18. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series.
Diamantopoulos AP; Hetland H; Myklebust G
Biomed Res Int; 2013; 2013():120638. PubMed ID: 24106691
[TBL] [Abstract][Full Text] [Related]
19. Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica.
De Miguel E; Karalilova R; Macchioni P; Ponte C; Conticini E; Cowley S; Tomelleri A; Monti S; Monjo I; Batalov Z; Klinowski G; Falsetti P; Kane DJ; Campochiaro C; Hočevar A
Ann Rheum Dis; 2024 Feb; 83(3):335-341. PubMed ID: 37932008
[TBL] [Abstract][Full Text] [Related]
20. Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis.
Salvarani C; Boiardi L; Macchioni P; Rossi F; Tartoni P; Casadei Maldini M; Mancini R; Beltrandi E; Portioli I
Ann Rheum Dis; 1995 Aug; 54(8):640-4. PubMed ID: 7677440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
